

# Treatment Options for Stage III Melanoma

---

- Resected Nodal Disease
  - IIIA ( $T_{1-2a}N_{1-2a}M_0$ ) (10 yr MSS: 88%)
    - If BRAF wild type:
      - Observation or Adjuvant Pembro or Nivolumab x1 year
    - If BRAFV600E mutated
      - Observation vs. Dabrafenib/Trametinib vs. Pembro or Nivolumab x1 year
  - IIIB/C/D (10 yr MSS: 77%, 60%, 24%, respectively)
    - If BRAF wild type:
      - Adjuvant Nivolumab (approved Dec 2017)
      - Adjuvant Pembro (approved Feb 2019)
    - If BRAFV600E mutated
      - Dabrafenib/Trametinib (approved April 2018) or Nivolumab or Pembro